In the HNSCC cell line, UMSCC74B and O28, afatinib inhibited EGFR and PI3K/Akt signaling and simultaneously induced the MEK/MAPK part of RAS signaling. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.